Wilson Sonsini Advises Freenome on IP Matters Related to Business Combination, Public Company Launch

July 22, 2026 - 04:49

On July 20, 2026, Freenome Holdings, Inc., a company focused on early cancer detection through blood-based screening tests, finalized its previously announced business combination. The deal marks the company's transition into a publicly traded entity. Wilson Sonsini Goodrich & Rosati, the prominent law firm, provided strategic counsel to Freenome on intellectual property matters tied to the merger and the subsequent public company launch.

The legal team worked to secure and align Freenome's patent assets and trade secrets with the demands of operating as a public corporation. This included addressing IP ownership, licensing agreements, and freedom-to-operate issues critical to the company's core technology. Freenome's platform uses a multi-omics approach, combining molecular biology and machine learning to detect cancer signals from a simple blood draw. Protecting that proprietary framework was a central focus of the advisory work.

Wilson Sonsini's involvement underscores the importance of robust IP strategy during complex corporate transactions. For a diagnostics company like Freenome, where intellectual property forms the backbone of competitive advantage, proper legal structuring can influence investor confidence and long-term market position. The business combination is expected to accelerate Freenome's clinical programs and regulatory efforts, with the newly public entity aiming to expand access to its non-invasive cancer screening tools.